Abstract 1180P
Background
METex14 skipping is present in 3–4% of patients with aNSCLC. Several MET-specific targeted therapies have recently been licensed, however the lack of randomized studies make inferences on comparative effectiveness complex. We evaluated treatment patterns and progression-free survival (PFS) using real-world data collected prior to the regulatory approvals of MET-specific tyrosine kinase inhibitors (TKIs).
Methods
Five real-world datasets of patients with METex14 skipping aNSCLC were pooled (data collected: 2011–2020); published data from a Western Canadian province, three international non-interventional studies, and French routine practice data. Patient records were included using a common data model with aligned definitions, and the best available definition of PFS was used.
Results
The analysis included 248 patients (54% female, 53% with smoking history), with a median age of 72 years. Of the 516 lines of therapy included, the majority could be categorized as chemotherapies (204), MET inhibitors (137; over 90% were crizotinib), or immunotherapy (119; mostly pembrolizumab and nivolumab). In general, patients received chemotherapy as a first-line therapy (118/220 identifiable lines). Across all treatment classes and treatment lines, median PFS (95% CI) were short; 5.0 (4.5, 7.5) vs 3.9 months (3.4, 5.2) for treatment-naïve vs previously treated patients receiving chemotherapy; 8.0 (4.0, 11.1) vs 7.0 months (5.6, 9.9) for MET inhibitors; and 3.6 (2.0, 10.2) vs 3.3 months (2.5, 5.7) for immunotherapies.
Conclusions
This international real-world analysis – conducted prior to the approval of MET-specific TKI therapies – showed that outcomes for patients with METex14 skipping aNSCLC were poor across all available therapy classes and treatment lines.
Clinical trial identification
Editorial acknowledgement
Medical writing assistance (funded by Merck Healthcare KGaA, Darmstadt, Germany) was provided by Syneos Health, London, UK.
Legal entity responsible for the study
Merck Healthcare KGaA, Darmstadt, Germany.
Funding
Merck Healthcare KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).
Disclosure
C. Ho: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Merck, Novartis, Pfizer, Roche, Takeda; Financial Interests, Institutional, Research Grant: AstraZeneca, EMD Serono, Roche; Non-Financial Interests, Principal Investigator: Roche, AstraZeneca, EMD Serono. A. Hatswell, R. Slater: Financial Interests, Personal, Full or part-time Employment: Delta Hat. H. Vioix: Financial Interests, Personal, Full or part-time Employment: Merck Healthcare KGaA, Darmstadt, Germany. C. Chouaid: Financial Interests, Personal, Advisory Board: AZ, BI, GSK, Roche, Sanofi-Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen; Financial Interests, Institutional, Funding: AZ, BI, GSK, Roche, Sanofi-Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen. All other authors have declared no conflicts of interest.